de Haas V - Search Results

1

Risk assessment in ALL in children: a focus on PCR-based techniques for MRD detection.

de Haas V, van der Schoot CE, van den Berg H. de Haas V, et al. Ann Oncol. 2001 May;12(5):587-92. doi: 10.1023/a:1011165510924. Ann Oncol. 2001. PMID: 11432614 Free article. Review. No abstract available.

2

Second allogeneic stem cell transplantation can rescue a significant proportion of patients with JMML relapsing after first allograft.

Vinci L, Flotho C, Noellke P, Lebrecht D, Masetti R, de Haas V, De Moerloose B, Dworzak M, Hasle H, Güngör T, Starý J, Turkiewicz D, Ussowicz M, de Heredia CD, Buechner J, Jahnukainen K, Kallay K, Bodova I, Smith OP, Zecca M, Bresters D, Lang P, Masmas TN, Meisel R, Pichler H, Erlacher M, Göhring G, Locatelli F, Strahm B, Niemeyer CM, Yoshimi A. Vinci L, et al. Among authors: de haas v. Bone Marrow Transplant. 2023 May;58(5):607-609. doi: 10.1038/s41409-023-01942-4. Epub 2023 Feb 23. Bone Marrow Transplant. 2023. PMID: 36823455 Free PMC article. No abstract available.

3

A joint international consensus statement for measuring quality of survival for patients with childhood cancer.

van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. van Kalsbeek RJ, et al. Nat Med. 2023 Jun;29(6):1340-1348. doi: 10.1038/s41591-023-02339-y. Epub 2023 Jun 15. Nat Med. 2023. PMID: 37322119 Review.

4

Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer.

van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. van Kalsbeek RJ, et al. Nat Med. 2024 Feb;30(2):603. doi: 10.1038/s41591-023-02651-7. Nat Med. 2024. PMID: 37963955 No abstract available.

5

Author Correction: A joint international consensus statement for measuring quality of survival for patients with childhood cancer.

van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. van Kalsbeek RJ, et al. Nat Med. 2024 Feb;30(2):605. doi: 10.1038/s41591-023-02753-2. Nat Med. 2024. PMID: 38092898 No abstract available.

6

Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.

Ramamoorthy S, Lebrecht D, Schanze D, Schanze I, Wieland I, Andrieux G, Metzger P, Hess M, Albert MH, Borkhardt A, Bresters D, Buechner J, Catala A, De Haas V, Dworzak M, Erlacher M, Hasle H, Jahnukainen K, Locatelli F, Masetti R, Stary J, Turkiewicz D, Vinci L, Wlodarski MW, Yoshimi A, Boerries M, Niemeyer CM, Zenker M, Flotho C. Ramamoorthy S, et al. Among authors: de haas v. Br J Haematol. 2024 Feb;204(2):595-605. doi: 10.1111/bjh.19190. Epub 2023 Nov 9. Br J Haematol. 2024. PMID: 37945316

7

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.

Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ. Pongers-Willemse MJ, et al. Among authors: de haas v. Leukemia. 1998 Dec;12(12):2006-14. doi: 10.1038/sj.leu.2401246. Leukemia. 1998. PMID: 9844931

8

Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reavtion identifies also patients with B-precursor acute lymphoblastic leukemia at high risk for relapse.

de Haas V, Breunis WB, Verhagen OJ, van der Berg H, van der Schoot CE. de Haas V, et al. Blood. 2000 Aug 15;96(4):1619-20. Blood. 2000. PMID: 10979670 Free article. No abstract available.

9

Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia.

de Haas V, Oosten L, Dee R, Verhagen OJ, Kroes W, van den Berg H, van der Schoot CE. de Haas V, et al. Br J Haematol. 2000 Dec;111(4):1080-6. doi: 10.1046/j.1365-2141.2000.02434.x. Br J Haematol. 2000. PMID: 11167743 Free article.

10

Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy.

de Haas V, Verhagen OJ, von dem Borne AE, Kroes W, van den Berg H, van der Schoot CE. de Haas V, et al. Leukemia. 2001 Jan;15(1):134-40. doi: 10.1038/sj.leu.2401970. Leukemia. 2001. PMID: 11243381

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

131 results

Search Page